Pharmacogenomics Market Size, Trends, Analysis, and Outlook By Products and Services (Kits & Reagents, Service), By Technology (Sequencing, PCR, Microarray, Others), By Disease (Cancer, Cardiovascular, Neurological Diseases, Others), By Application (Personalized Medicine, Clinical Research, Drug discovery & Preclinical Development), By End-User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations), by Country, Segment, and Companies, 2024-2032
The global Pharmacogenomics market size is poised to register 11.5% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Pharmacogenomics market across By Products and Services (Kits & Reagents, Service), By Technology (Sequencing, PCR, Microarray, Others), By Disease (Cancer, Cardiovascular, Neurological Diseases, Others), By Application (Personalized Medicine, Clinical Research, Drug discovery & Preclinical Development), By End-User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations)
The future of the pharmacogenomics market is driven by advancements in genomics technology, increasing understanding of genetic factors influencing drug response, and growing applications in precision medicine and personalized drug therapy. Pharmacogenomics, also known as personalized medicine or precision medicine, is the study of how an individual's genetic makeup influences their response to drugs, including drug efficacy, safety, and tolerability. With the rise of genomic sequencing technologies, bioinformatics tools, and electronic health records (EHRs), there is a growing need for pharmacogenomic solutions that offer comprehensive genomic profiling, interpretation of genetic variants, and clinical decision support to guide drug selection, dosing, and monitoring for optimal therapeutic outcomes. Further, technological innovations such as point-of-care genetic testing, pharmacogenomic databases, and AI-driven predictive models are driving the development of next-generation pharmacogenomic solutions with improved accessibility, affordability, and clinical utility for healthcare providers and patients. Over the forecast period to 2030, expanding applications in oncology, psychiatry, and cardiovascular medicine, coupled with increasing regulatory support for pharmacogenomic testing and reimbursement policies, are expected to drive market growth and innovation, enabling healthcare organizations to integrate genomic information into routine clinical practice, improve patient outcomes, and reduce healthcare costs.
Pharmacogenomics Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Pharmacogenomics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Pharmacogenomics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Pharmacogenomics industry.
Key market trends defining the global Pharmacogenomics demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Pharmacogenomics Market Segmentation- Industry Share, Market Size, and Outlook to 2032
The Pharmacogenomics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Pharmacogenomics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Pharmacogenomics industry
Leading Pharmacogenomics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Pharmacogenomics companies.
Pharmacogenomics Market Study- Strategic Analysis Review
The Pharmacogenomics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Pharmacogenomics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.
Pharmacogenomics Country Analysis and Revenue Outlook to 2032
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.
North America Pharmacogenomics Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Pharmacogenomics market segments. Similarly, Strong market demand is encouraging Canadian Pharmacogenomics companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Pharmacogenomics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Pharmacogenomics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Pharmacogenomics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Pharmacogenomics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Pharmacogenomics Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Pharmacogenomics in Asia Pacific. In particular, China, India, and South East Asian Pharmacogenomics markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.
Latin America Pharmacogenomics Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Pharmacogenomics Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Pharmacogenomics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Pharmacogenomics.
Pharmacogenomics Market Company Profiles
The global Pharmacogenomics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Agilent Technologies Inc, Becton, Dickinson and Company, BGI Genomics Co. Ltd (BGI), Bio-Rad Laboratories Inc, Charles River Laboratories International Inc, Danaher Corp, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Illumina Inc, IQVIA Holdings Inc, Laboratory Corp of America Holdings (LabCorp), Medpace Holdings Inc, Mesa Laboratories Inc, MGI Tech Co. Ltd, New England Biolabs Inc, Novogene Corp Ltd, Pacific Biosciences of California Inc (PacBio), QIAGEN N.V., Revvity Health Inc, Takara Bio Inc, Thermo Fisher Scientific Inc.
Recent Pharmacogenomics Market Developments
The global Pharmacogenomics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Pharmacogenomics Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Products and Services
Kits & Reagents
Service
By Technology
Sequencing
PCR
Microarray
Others
By Disease
Cancer
Cardiovascular
Neurological Diseases
Others
By Application
Personalized Medicine
Clinical Research
Drug discovery & Preclinical Development
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Geographical Segmentation:
Agilent Technologies Inc
Becton, Dickinson and Company
BGI Genomics Co. Ltd (BGI)
Bio-Rad Laboratories Inc
Charles River Laboratories International Inc
Danaher Corp
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
Illumina Inc
IQVIA Holdings Inc
Laboratory Corp of America Holdings (LabCorp)
Medpace Holdings Inc
Mesa Laboratories Inc
MGI Tech Co. Ltd
New England Biolabs Inc
Novogene Corp Ltd
Pacific Biosciences of California Inc (PacBio)
QIAGEN N.V.
Revvity Health Inc
Takara Bio Inc
Thermo Fisher Scientific Inc
Formats Available: Excel, PDF, and PPT
The future of the pharmacogenomics market is driven by advancements in genomics technology, increasing understanding of genetic factors influencing drug response, and growing applications in precision medicine and personalized drug therapy. Pharmacogenomics, also known as personalized medicine or precision medicine, is the study of how an individual's genetic makeup influences their response to drugs, including drug efficacy, safety, and tolerability. With the rise of genomic sequencing technologies, bioinformatics tools, and electronic health records (EHRs), there is a growing need for pharmacogenomic solutions that offer comprehensive genomic profiling, interpretation of genetic variants, and clinical decision support to guide drug selection, dosing, and monitoring for optimal therapeutic outcomes. Further, technological innovations such as point-of-care genetic testing, pharmacogenomic databases, and AI-driven predictive models are driving the development of next-generation pharmacogenomic solutions with improved accessibility, affordability, and clinical utility for healthcare providers and patients. Over the forecast period to 2030, expanding applications in oncology, psychiatry, and cardiovascular medicine, coupled with increasing regulatory support for pharmacogenomic testing and reimbursement policies, are expected to drive market growth and innovation, enabling healthcare organizations to integrate genomic information into routine clinical practice, improve patient outcomes, and reduce healthcare costs.
Pharmacogenomics Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Pharmacogenomics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Pharmacogenomics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Pharmacogenomics industry.
Key market trends defining the global Pharmacogenomics demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Pharmacogenomics Market Segmentation- Industry Share, Market Size, and Outlook to 2032
The Pharmacogenomics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Pharmacogenomics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Pharmacogenomics industry
Leading Pharmacogenomics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Pharmacogenomics companies.
Pharmacogenomics Market Study- Strategic Analysis Review
The Pharmacogenomics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Pharmacogenomics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.
Pharmacogenomics Country Analysis and Revenue Outlook to 2032
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.
North America Pharmacogenomics Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Pharmacogenomics market segments. Similarly, Strong market demand is encouraging Canadian Pharmacogenomics companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Pharmacogenomics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Pharmacogenomics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Pharmacogenomics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Pharmacogenomics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Pharmacogenomics Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Pharmacogenomics in Asia Pacific. In particular, China, India, and South East Asian Pharmacogenomics markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.
Latin America Pharmacogenomics Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Pharmacogenomics Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Pharmacogenomics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Pharmacogenomics.
Pharmacogenomics Market Company Profiles
The global Pharmacogenomics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Agilent Technologies Inc, Becton, Dickinson and Company, BGI Genomics Co. Ltd (BGI), Bio-Rad Laboratories Inc, Charles River Laboratories International Inc, Danaher Corp, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Illumina Inc, IQVIA Holdings Inc, Laboratory Corp of America Holdings (LabCorp), Medpace Holdings Inc, Mesa Laboratories Inc, MGI Tech Co. Ltd, New England Biolabs Inc, Novogene Corp Ltd, Pacific Biosciences of California Inc (PacBio), QIAGEN N.V., Revvity Health Inc, Takara Bio Inc, Thermo Fisher Scientific Inc.
Recent Pharmacogenomics Market Developments
The global Pharmacogenomics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Pharmacogenomics Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Products and Services
Kits & Reagents
Service
By Technology
Sequencing
PCR
Microarray
Others
By Disease
Cancer
Cardiovascular
Neurological Diseases
Others
By Application
Personalized Medicine
Clinical Research
Drug discovery & Preclinical Development
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
Agilent Technologies Inc
Becton, Dickinson and Company
BGI Genomics Co. Ltd (BGI)
Bio-Rad Laboratories Inc
Charles River Laboratories International Inc
Danaher Corp
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
Illumina Inc
IQVIA Holdings Inc
Laboratory Corp of America Holdings (LabCorp)
Medpace Holdings Inc
Mesa Laboratories Inc
MGI Tech Co. Ltd
New England Biolabs Inc
Novogene Corp Ltd
Pacific Biosciences of California Inc (PacBio)
QIAGEN N.V.
Revvity Health Inc
Takara Bio Inc
Thermo Fisher Scientific Inc
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Pharmacogenomics Market Overview and Key Findings, 2024
1.2 Pharmacogenomics Market Size and Growth Outlook, 2021- 2030
1.3 Pharmacogenomics Market Growth Opportunities to 2030
1.4 Key Pharmacogenomics Market Trends and Challenges
1.4.1 Pharmacogenomics Market Drivers and Trends
1.4.2 Pharmacogenomics Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Pharmacogenomics Companies
2. PHARMACOGENOMICS MARKET SIZE OUTLOOK TO 2030
2.1 Pharmacogenomics Market Size Outlook, USD Million, 2021- 2030
2.2 Pharmacogenomics Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. PHARMACOGENOMICS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. PHARMACOGENOMICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Products and Services
Kits & Reagents
Service
By Technology
Sequencing
PCR
Microarray
Others
By Disease
Cancer
Cardiovascular
Neurological Diseases
Others
By Application
Personalized Medicine
Clinical Research
Drug discovery & Preclinical Development
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Pharmacogenomics Market, 2025
5.2 Asia Pacific Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Pharmacogenomics Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Pharmacogenomics Market, 2025
5.5 Europe Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.6 Europe Pharmacogenomics Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Pharmacogenomics Market, 2025
5.8 North America Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.9 North America Pharmacogenomics Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Pharmacogenomics Market, 2025
5.11 South America Pacific Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.12 South America Pharmacogenomics Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Pharmacogenomics Market, 2025
5.14 Middle East Africa Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Pharmacogenomics Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Pharmacogenomics Market Size Outlook and Revenue Growth Forecasts
6.2 US Pharmacogenomics Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Pharmacogenomics Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Pharmacogenomics Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Pharmacogenomics Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Pharmacogenomics Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Pharmacogenomics Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Pharmacogenomics Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Pharmacogenomics Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Pharmacogenomics Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Pharmacogenomics Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Pharmacogenomics Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Pharmacogenomics Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Pharmacogenomics Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Pharmacogenomics Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Pharmacogenomics Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Pharmacogenomics Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Pharmacogenomics Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Pharmacogenomics Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Pharmacogenomics Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Pharmacogenomics Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Pharmacogenomics Industry Drivers and Opportunities
7. PHARMACOGENOMICS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. PHARMACOGENOMICS COMPANY PROFILES
8.1 Profiles of Leading Pharmacogenomics Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Agilent Technologies Inc
Becton, Dickinson and Company
BGI Genomics Co. Ltd (BGI)
Bio-Rad Laboratories Inc
Charles River Laboratories International Inc
Danaher Corp
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
Illumina Inc
IQVIA Holdings Inc
Laboratory Corp of America Holdings (LabCorp)
Medpace Holdings Inc
Mesa Laboratories Inc
MGI Tech Co. Ltd
New England Biolabs Inc
Novogene Corp Ltd
Pacific Biosciences of California Inc (PacBio)
QIAGEN N.V.
Revvity Health Inc
Takara Bio Inc
Thermo Fisher Scientific Inc.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Pharmacogenomics Market Overview and Key Findings, 2024
1.2 Pharmacogenomics Market Size and Growth Outlook, 2021- 2030
1.3 Pharmacogenomics Market Growth Opportunities to 2030
1.4 Key Pharmacogenomics Market Trends and Challenges
1.4.1 Pharmacogenomics Market Drivers and Trends
1.4.2 Pharmacogenomics Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Pharmacogenomics Companies
2. PHARMACOGENOMICS MARKET SIZE OUTLOOK TO 2030
2.1 Pharmacogenomics Market Size Outlook, USD Million, 2021- 2030
2.2 Pharmacogenomics Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. PHARMACOGENOMICS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. PHARMACOGENOMICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Products and Services
Kits & Reagents
Service
By Technology
Sequencing
PCR
Microarray
Others
By Disease
Cancer
Cardiovascular
Neurological Diseases
Others
By Application
Personalized Medicine
Clinical Research
Drug discovery & Preclinical Development
By End-User
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Pharmacogenomics Market, 2025
5.2 Asia Pacific Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Pharmacogenomics Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Pharmacogenomics Market, 2025
5.5 Europe Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.6 Europe Pharmacogenomics Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Pharmacogenomics Market, 2025
5.8 North America Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.9 North America Pharmacogenomics Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Pharmacogenomics Market, 2025
5.11 South America Pacific Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.12 South America Pharmacogenomics Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Pharmacogenomics Market, 2025
5.14 Middle East Africa Pharmacogenomics Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Pharmacogenomics Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Pharmacogenomics Market Size Outlook and Revenue Growth Forecasts
6.2 US Pharmacogenomics Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Pharmacogenomics Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Pharmacogenomics Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Pharmacogenomics Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Pharmacogenomics Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Pharmacogenomics Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Pharmacogenomics Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Pharmacogenomics Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Pharmacogenomics Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Pharmacogenomics Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Pharmacogenomics Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Pharmacogenomics Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Pharmacogenomics Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Pharmacogenomics Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Pharmacogenomics Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Pharmacogenomics Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Pharmacogenomics Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Pharmacogenomics Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Pharmacogenomics Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Pharmacogenomics Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Pharmacogenomics Industry Drivers and Opportunities
7. PHARMACOGENOMICS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. PHARMACOGENOMICS COMPANY PROFILES
8.1 Profiles of Leading Pharmacogenomics Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Agilent Technologies Inc
Becton, Dickinson and Company
BGI Genomics Co. Ltd (BGI)
Bio-Rad Laboratories Inc
Charles River Laboratories International Inc
Danaher Corp
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
Illumina Inc
IQVIA Holdings Inc
Laboratory Corp of America Holdings (LabCorp)
Medpace Holdings Inc
Mesa Laboratories Inc
MGI Tech Co. Ltd
New England Biolabs Inc
Novogene Corp Ltd
Pacific Biosciences of California Inc (PacBio)
QIAGEN N.V.
Revvity Health Inc
Takara Bio Inc
Thermo Fisher Scientific Inc.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
